Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Obsidian Therapeutics logo — At Obsidian, our vision is pioneering engineered cell & gene...

Obsidian Therapeutics

At Obsidian, our vision is pioneering engineered cell & gene therapies to deliver transformative outcomes for patients.

Founded 2015 United States Cambridge, United States 107 employees Total: $675.00M Biotechnology, Health Care +1

General Information

Company Name Obsidian Therapeutics
Founded Year 2015
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 107
Industries Biotechnology, Health Care, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with Obsidian Therapeutics. To contact Obsidian Therapeutics, visit obsidiantx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Obsidian Therapeutics compare?

A PDF of Obsidian Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Obsidian Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Obsidian Therapeutics

Obsidian Therapeutics, founded in 2015, is a **biotechnology** startup based in the United States, with a recent Series B investment of $115.00M on 09 September 2021. The company's focus lies in pioneering controllable cell and gene therapies to provide breakthrough solutions for patients suffering from intractable diseases. Obsidian's innovative approach involves utilizing their cytoDriveTM technology in cell and gene therapy products to regulate the expression of proteins, thereby enhancing therapeutic efficacy. Their lead program, cytoTIL15, aims to improve the effectiveness of TILs for a wider range of patients. Obsidian Therapeutics boasts a well-funded status with investments from prominent names such as **Amgen Ventures**, **Atlas Venture**, **RA Capital Management**, **The Column Group**, **Deep Track Capital**, **Logos Capital**, **Samsara BioCapital**, **TCG Crossover**, **Vertex Ventures HC**, and **Bristol-Myers Squibb**. This significant financial backing, along with a diverse and talented team, strategic partnerships with industry leaders, and a state-of-the-art laboratory facility in Bedford, positions the company to deliver on its ambitious goals. The company’s headquarters in the heart of Cambridge reflects its commitment to being at the forefront of innovation in the biotechnology and healthcare sectors. Obsidian also emphasizes creating an inclusive environment where each team member can thrive, while offering competitive salary and benefits, as well as the potential for employee ownership through stock options. With a strong vision and the necessary resources, Obsidian Therapeutics is poised to make significant advancements in addressing critical clinical needs and revolutionizing patient care with cutting-edge therapies.

Business keywords: Cell therapy, Gene therapy, Controllable therapies, CytoDrive technology, Transformative outcomes, Intractable diseases, Clinical need, Cambridge, Bedford, Diverse team, Inclusion, Employee ownership, Clinical efficacy, Investor-backed

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement VC $350.00M -
01 Apr 2026
Series C $160.50M 17
Novo Holdings Atlas Venture RA Capital Management
Novo Holdings, Atlas Venture +15
01 Apr 2024
Series B $115.00M 5
Amgen Ventures Atlas Venture RA Capital Management
Amgen Ventures, Atlas Venture +3
01 Sep 2021
Series A $49.50M 6
Amgen Ventures Atlas Venture GV
Amgen Ventures, Atlas Venture +4
01 Dec 2017

Obsidian Therapeutics Alternatives & Competitors

View All Alternatives
Obsidian Therapeutics vs
PuREC Co.Ltd.
PuREC Co.Ltd. Japan

Ultra-pure human bone marrow derived mesenchymal stem cell “REC”

Series A
4 employees
Health Care, Health and Wellness
Compare Obsidian Therapeutics vs PuREC Co.Ltd.
Obsidian Therapeutics vs
AAVantgarde
AAVantgarde

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care
Compare Obsidian Therapeutics vs AAVantgarde
Obsidian Therapeutics vs
Mustang Bio
Mustang Bio United States

A fortress biotech Company

IPO
43 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Obsidian Therapeutics

At Obsidian, our vision is pioneering engineered cell & gene therapies to deliver transformative outcomes for patients.
Obsidian Therapeutics was founded in 2015.
Obsidian Therapeutics is headquartered in Cambridge, United States.
Obsidian Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Cell therapy, Gene therapy, Controllable therapies and CytoDrive technology.
Obsidian Therapeutics has approximately 107 employees.
Obsidian Therapeutics has completed 4 funding rounds, raising a total of $675.00M.
Top alternatives and competitors to Obsidian Therapeutics include PuREC Co.Ltd., AAVantgarde, Mustang Bio, A2 Biotherapeutics, Inc., Caribou Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Obsidian Therapeutics and PuREC Co.Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Obsidian Therapeutics, https://bouncewatch.com/company/obsidian-therapeutics, updated 25 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout